期刊文献+

帕金森病脑内铁沉积含量磁敏感成像临床研究 被引量:3

Susceptibility weighted imaging evaluation of brain iron content in patients with parkinson’s disease
下载PDF
导出
摘要 目的应用磁敏感加权成像技术相位图测定帕金森病(PD)患者脑内铁沉积含量,并探讨其在临床研究中的意义。方法应用磁敏感加权成像技术测定20例PD患者(PD组)和25名健康人(对照组)各感兴趣区域(ROI)中双侧苍白球(GP)、壳核(Pu)、尾状核(CN)、前脑白质、黑质(SN)和红核(RN)的相位值,并分析相位值与脑内铁沉积含量及PD临床指标的相关性。结果对照组的相位值与脑内铁沉积定量研究数据呈负相关(r=-0.932,P=0.007)。对照组不同性别间各ROI的相位值的差异均无统计学意义(P值均>0.05);CN的相位值与年龄呈负相关(r=-0.562,P=0.004),其他ROI的相位值与年龄和性别均不相关(P值均>0.05)。PD组症状严重侧肢体对侧的黑质网状(SNr)中部(-0.19896±0.18746,t=3.137,P=0.006)和黑质网状(SNr)侧部(-0.17324±0.14542,t=2.288,P=0.034)的相位值均显著小于症状较轻侧肢体对侧(-0.09725±0.10176、-0.06879±0.11243,P值均<0.05),其他ROI的相对值的差异均无统计学意义(P值均>0.05)。PD统一评分量表第三部分中单侧肢体得分与对应的各ROI的相位值均不相关(P值均>0.05);SNr侧部(r=-0.584,P=0.009)、RN(r=-0.640,P=0.003)的相位值分别与病程呈负相关;其他ROI的相位值与患者的年龄、病程均不相关(P值均>0.05)。两组不同性别和年龄间的相位值的差异均无统计学意义(P值均>0.05)。PD组在SNr侧部上的相位值(-0.01371±0.10595)显著小于对照组(-0.0057±0.0975,t=-2.828,P=0.008),两组间其他ROI的相位值间的差异均无统计学意义(P值均>0.05)。结论应用磁敏感加权成像技术测定脑内铁沉积含量对PD的临床诊断具有一定的应用价值,脑内铁沉积含量与病程及肢体运动障碍严重程度有关。 Objective To compare the iron deposition quantified by susceptibility weighted imaging (SWI) in several cerebral regions between Parkinson's disease patients and control subjects, and evaluate the possibilities of clinical application. Methods 20 patients with PD and 25 healthy adults performed MR examination with a 3.0 tesla magnet. The regions of interest (ROI) evaluated included globus pallidus (GP), putamen (Pu), caudate nucleus (ON), anterior white matter, substantia nigra pars reticulate (SNr), substantia nigra pars compacta (SNc) and red nucleus (RN), and corresponding signals and phase values were measured. Results In healthy adults, there was negative correlation between phase value and brain iron deposition (r = -0. 932, P =0. 007); there was no significant difference in phase value between male and female (P〉O. 05); there was negative correlation between phase value and age (r = -0. 562, P = 0. 004); the phase value in other ROI has no correlation with age and sex (all P〉O. 05). In PD patients the phase values of medial SNr ( t=3. 137, P = 0. 006) and lateral SNr ( t = 2. 288, P = 0. 034) opposite the clinically more affected side ( - 0. 198 96 ± 0. 187 46, - 0. 173 24 - 0. 145 42) were smaller than those opposite the less affected side ( - 0. 097 25 ±0. 101 76, -0. 068 79± 0.112 43) in patients; the phase value of other ROI has no significant difference (all P〈 0.05)] there was no correlation between phase value and scores of unilateral limbs in UPDRS Ⅲ there was negative correlation between phase value of lateral SNc ( r = - 0. 584, P = 0. 009) and RN ( r = - 0. 640, P = 0. 003) and course of disease in patients. The phase value of lateral SNc in PD patients were smaller than those in control subjects (t= 2. 828, P = 0. 008). The phase value of other ROI has no significant difference (all P〉 0.05). Conclusions It has application value of clinical diagnosis of PD that detect of the brain iron deposition using SWl, Iron deposition correlates with courses of PD disease, and it more affected side was more than those opposite the less affected side in patients.
出处 《上海医学》 CAS CSCD 北大核心 2012年第11期969-972,F0003,共5页 Shanghai Medical Journal
基金 上海市科学技术委员会纳米技术专项(11nm0503300) 国家自然科学基金(81071025)资助项目
关键词 帕金森病 铁沉积 磁敏感加权成像技术 磁共振成像 Parkinson s disease Iron Susceptibility weighted imaging Magnetic resonance imaging
  • 相关文献

参考文献15

  • 1BERG D,GROTE C,RAUSCH W D. Iron accumulation in the substantia nigra in rats visualized by ultrasound[J].Ultrasound in Medicine and Biology,1999,(06):901-904.doi:10.1016/S0301-5629(99)00046-0.
  • 2CONNOR Jr,SNYDER B S,AROSIO P. A quantitative analysis of isoferritins in select regions of aged,parkinsonian,and Alzheimer' s diseased brains[J].Journal of Neurochemistry,1995,(02):717-724.
  • 3HAACKE E M,AYAZ M,KHAN A. Establishing a baseline phase behavior in magnetic resonance imaging to determine normal vs.abnormal iron content in the brain[J].Journal of Magnetic Resonance Imaging,2007,(02):256-264.doi:10.1002/jmri.22987.
  • 4HALLGREN B,SOURANDER P. The effect of age on the non-haemin iron in the human brain[J].Journal of Neurochemistry,1958,(01):41-51.
  • 5LOEFFLER D A,CONNOR Jr,JUNEAU P L. Transferrin and iron in normal,Alzheimer' s disease,and Parkinson's disease brain regions[J].Journal of Neurochemistry,1995,(02):710-724.
  • 6BARTZOKIS G,MINTZ J,SULTZER D. Invivo MR evaluation of age-related increases in brain iron[J].American Journal of Neuroradiology,1994,(06):1129-1138.
  • 7MARTIN W R,YE F Q,ALLEN P S. Increasing striatal iron content associated with normal aging[J].Movement Disorders,1998,(02):281-286.
  • 8BRASS S D,CHEN N K,MULKERN R V. Maguetic resonance imaging of iron deposition in neurological disorders[J].Topics in Magnetic Resonance Imaging,2006,(01):31-40.
  • 9ORDIDGE R J,GORELL J M,DENIAU J C. Assessment of relative brain iron concentrations using T2-weighted and T2 * weighted MRI at 3 Tesla[J].Magnetic Resonance in Medicine,1994,(03):335-341.
  • 10GRAHAM J M,PALEY M N,GR(U)NEWALD R A. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence[J].Brain,2000,(Pt 12):2423-2431.

同被引文献46

  • 1赵望.磁敏感加权成像在帕金森病中的应用研究[J].医学信息(医学与计算机应用),2014,0(21):118-119. 被引量:1
  • 2白雪松,金辉,黄学洙.Klotho蛋白与老年人术后认知功能障碍的关系[J].中国老年学杂志,2015,35(1):3-4. 被引量:8
  • 3Waragai M, Sekiyama K, Sekigawa A, et al. alpha-Synuclein and DJ 1 as potential biological fluid biomarkers for Parkinson's dis ease. Int J Mol Sci, 2010,11(11):4257-4266.
  • 4Jesse S, Steinacker P, Lehnert S, et al. Neuroehemical approa- ches in the laboratory diagnosis of Parkinson and Parkinson de- mentia syndromes: A review. CNS Neurosei Ther, 2009,15(2):157-182.
  • 5Salazar J, Mena N, Hunot S, et al. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci U S A, 2008, 105(47): 18578-18583.
  • 6Sofic E, Riederer P, Heinsen H, et al. Increased iron ( III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm, 1988,74(3) : 199-205.
  • 7Oakley AE, Collingwood JF, Dobson J, et al. Individual dopam- inergic neurons show raised iron levels in Parkinson disease. Neu- rology, 2007,68(21) : 1820-1825.
  • 8Zhang J, Zhang Y, Wang J, et al. Characterizing iron deposi- tion in Parkinson's disease using susceptibility weighted imaging: An in vivo MR study. Brain Res, 2010,1330:124-130.
  • 9Zhang W, Sun SG, Jiang YH, et al. Determination of brain iron content in patients with Parkinson's disease using magnetic sus- ceptibility imaging. Neurosci Bull, 2009,25(6):353-360.
  • 10Acosta-cabronero J, Williams GB, Cardenas-blanco A, et al. In vivo quantitative susceptibility mapping (QSM) in Alzheimer's disease. PLoS One, 2013,8(11):e81093.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部